Who
Adam Laponis
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Twist Bioscience; Chief Financial Officer, Eargo.
In numbers
- Trades disclosed
- 77
- Buys
- 0
- Sells
- 34
- Bought
- $0
- Sold
- $8.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 20 Oct 2020
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $385K2,462 at $156.30 | filing |
| 2 Oct 2026filed 5 Oct 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $1.5M8,057 at $188.88 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $273K1,965 at $139.07 | filing |
| 21 Aug 2026filed 25 Aug 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $273K1,965 at $139.07 | filing |
| 9 Jul 2026filed 13 Jul 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $226K2,399 at $94.33 | filing |
| 9 Jul 2026filed 13 Jul 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $226K2,399 at $94.33 | filing |
| 29 May 2026filed 2 Jun 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $280K4,000 at $70.00 | filing |
| 29 May 2026filed 2 Jun 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $280K4,000 at $70.00 | filing |
| 21 May 2026filed 26 May 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $108K2,019 at $53.26 | filing |
| 21 May 2026filed 26 May 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $108K2,019 at $53.26 | filing |
| 17 Apr 2026filed 21 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $240K4,000 at $60.00 | filing |
| 17 Apr 2026filed 21 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $240K4,000 at $60.00 | filing |
| 14 Apr 2026filed 16 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $165K3,000 at $55.00 | filing |
| 14 Apr 2026filed 16 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $165K3,000 at $55.00 | filing |
| 9 Apr 2026filed 13 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $130K2,597 at $49.89 | filing |
| 9 Apr 2026filed 13 Apr 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $130K2,597 at $49.89 | filing |
| 23 Feb 2026filed 25 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $97K2,085 at $46.71 | filing |
| 23 Feb 2026filed 25 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $97K2,085 at $46.71 | filing |
| 12 Feb 2026filed 13 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $350K7,000 at $50.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Sold | $350K7,000 at $50.00 | filing |
News
Twist Bioscience (NASDAQ:TWST) versus Quanterix (NASDAQ:QTRX) Financial AnalysisTWST · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Adam Laponis; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.